Aclaris Therapeutics Inc. (ACRS) Stock Price Up 2.4%
Aclaris Therapeutics Inc. (NASDAQ:ACRS) rose 2.4% during trading on Friday . The company traded as high as $20.99 and last traded at $20.71, with a volume of 68,783 shares trading hands. The stock had previously closed at $20.23.
ACRS has been the subject of a number of research reports. Guggenheim began coverage on shares of Aclaris Therapeutics in a report on Friday, June 10th. They issued a “buy” rating and a $35.00 target price for the company. Zacks Investment Research raised shares of Aclaris Therapeutics from a “sell” rating to a “hold” rating in a report on Friday, June 17th. Finally, Jefferies Group increased their price target on shares of Aclaris Therapeutics from $20.00 to $23.00 and gave the stock a “buy” rating in a report on Friday, August 12th. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average price target of $29.25.
The stock’s market capitalization is $457.00 million. The stock has a 50-day moving average of $19.96 and a 200-day moving average of $19.14.
Aclaris Therapeutics (NASDAQ:ACRS) last released its quarterly earnings results on Thursday, August 11th. The company reported ($0.62) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.61) by $0.01. Equities analysts predict that Aclaris Therapeutics Inc. will post ($2.61) EPS for the current fiscal year.
Aclaris Therapeutics, Inc is a United States-based clinical-stage specialty pharmaceutical company. The Company is focused on identifying, developing and commercializing differentiated therapies in dermatology. The Company’s drug candidate, A-101 is being developed as an in-office treatment for seborrheic keratosis, a non-cancerous skin tumor, as well as for other cutaneous indications, such as common warts.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.